PharmiWeb.com - Global Pharma News & Resources
15-May-2023

Validant Group Announces New Leadership

Tim Dietlin Joins the Company as CEO

WASHINGTON--(BUSINESS WIRE)--The Validant Group, a leading international quality, compliance, and regulatory consulting firm, today announces that Tim Dietlin has joined the company in the role of Chief Executive Officer (CEO).

“Tim brings a unique skill set to his role as CEO of the Validant Group. His deep understanding of the life sciences industry, coupled with his business effectiveness and leadership advisory experience, allows Tim to build transformative teams that drive growth and attain long-term success,” said Alistair Macdonald, Chair of the Validant Group Board of Directors and ­­Operating Partner, GHO Capital.



Tim Dietlin brings more than 25 years of leadership experience to his role as CEO of the Validant Group. Most recently, Tim served for eight years as the Global Managing Partner of the Healthcare and Life Sciences Practice at Heidrick & Struggles, a leading global executive search and management consulting firm. In this role, Tim led all aspects of the practice’s healthcare and life sciences business and specialized in providing leadership advisory services to a broad portfolio of clients, including established pharmaceutical companies, emerging high-growth biotechnology firms, and investor backed service and technology companies.

Tim’s extensive experience includes leadership roles at IBM, where he led the life sciences strategy and transformation consulting practice; INC Research, where he served as Senior Vice President of Global Consulting and Strategic Alliances; and Campbell Alliance, a life sciences management consulting firm, where Tim led the firm’s Research and Development and Medical Affairs consulting practices.

“The Validant Group has built a strong foundation as a leader in the life sciences industry. By uniting this already powerful partnership of companies, and capitalizing on our collective capabilities, we will unlock the full potential of our business,” said Tim Dietlin, Validant Group CEO. “Together, the Validant Group will deliver a full-service platform that provides unmatched regulatory clarity at every phase of the product life cycle. I look forward to cultivating and continuing to grow a united Validant Group that is stronger together and positioned for success.”

ABOUT THE VALIDANT GROUP

The Validant Group is a global, full-service life science consulting company focused on managing and resolving complex regulatory issues. The Validant Group is comprised of five companies offering collaborative consultancy services:

Validant: An international Quality, Compliance, and Regulatory consulting firm, blending industry expertise with innovation to create custom solutions for companies on the frontier of health. For further information, please visit www.validant.com

Greenleaf Health: A leading FDA regulatory consulting firm that provides best-in-class strategic and technical guidance to pharmaceutical, biotechnology, and medical device companies regulated by the FDA. For further information, please visit www.greenleafhealth.com

Oriel Stat-A-Matrix (OSAM): A consultancy and training firm focused on medical device regulatory compliance, quality management, auditing, and training for US and international regulations. For further information, please visit www.orielstat.com

DataRevive: A global regulatory consulting company helping pharmaceutical and biotech companies with their regulatory filings. For further information, please visit www.data-revive.com

IDEC: A strategic consultancy firm providing regulatory guidance to biotechnology and pharmaceutical companies developing products for the Japanese market. For further information, please visit www.idec-inc.com

The Validant Group’s growth strategy is supported by GHO Capital Partners LLP, a leading specialist healthcare investment advisor based in London. GHO applies global capabilities and perspectives to unlock high growth healthcare opportunities in Europe, building market leading businesses of strategic global value. GHO’s proven investment track record reflects the unrivalled depth of its industry expertise and network. GHO partners with strong management teams to unlock value in a global system that demands the delivery of better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.


Contacts

Taryn.Walpole@greenleafhealth.com

Editor Details

  • Company:
    • Businesswire
Last Updated: 15-May-2023